Abstract
Many patients with chronic migraine abuse symptomatic medications, have drug-induced headaches, psychiatric comorbidities and respond poorly to conventional preventive therapy. In these cases, the terms “resistant” and “refractory migraine” are used and an expanded therapeutic armamentarium is recommended. Currently, the use of monoclonal antibodies against calcitonin gene-related peptide is the best-studied and most effective method of preventive therapy in resistant migraine cases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
